Palisade Bio Company Top Insiders
| PALI Stock | USD 2.23 0.08 3.72% |
Palisade Bio employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Assessment of Palisade Bio's management performance can provide insight into the firm performance.
Palisade Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.8781) % which means that it has lost $0.8781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.2864) %, meaning that it created substantial loss on money invested by shareholders. Palisade Bio's management efficiency ratios could be used to measure how well Palisade Bio manages its routine affairs as well as how well it operates its assets and liabilities.Palisade Bio Workforce Comparison
Palisade Bio is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 77,844. Palisade Bio adds roughly 8.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Palisade Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Palisade Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Palisade Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Palisade Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
J Finley over three weeks ago Disposition of 2111 shares by J Finley of Palisade Bio subject to Rule 16b-3 | ||
J Finley over a month ago Acquisition by J Finley of 666 shares of Palisade Bio at 4.9725 subject to Rule 16b-3 | ||
Chuang Emil over a month ago Acquisition by Chuang Emil of 510700 shares of Palisade Bio subject to Rule 16b-3 | ||
Wei Binxian over two months ago Acquisition by Wei Binxian of 388 shares of Palisade Bio subject to Rule 16b-3 | ||
Diaz Stephanie over two months ago Disposition of 9580 shares by Diaz Stephanie of Palisade Bio at 1.6 subject to Rule 16b-3 | ||
Chuang Emil over two months ago Acquisition by Chuang Emil of 18800 shares of Palisade Bio subject to Rule 16b-3 | ||
Chuang Emil over three months ago Insider Trading | ||
Chuang Emil over three months ago Insider Trading |
Palisade Bio Notable Stakeholders
A Palisade Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Palisade Bio often face trade-offs trying to please all of them. Palisade Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Palisade Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| J Finley | CEO Director | Profile | |
| Joerg Heyer | Head Medicine | Profile | |
| Ryker Willie | Senior Controller | Profile | |
| Sharon McBrayer | Director Operations | Profile | |
| Mitchell MD | Chief Officer | Profile | |
| Sharon Skare | Vice Operations | Profile | |
| Robert McRae | VP Devel | Profile | |
| MD FAAAAI | Chief Officer | Profile |
About Palisade Bio Management Performance
The success or failure of an entity such as Palisade Bio often depends on how effective the management is. Palisade Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Palisade management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Palisade management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. The company was founded in 2005 and is headquartered in Carlsbad, California. Palisade Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Palisade Bio Workforce Analysis
Traditionally, organizations such as Palisade Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Palisade Bio within its industry.Palisade Bio Manpower Efficiency
Return on Palisade Bio Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.8M | |
| Net Loss Per Executive | 1.8M | |
| Working Capital Per Employee | 907.2K | |
| Working Capital Per Executive | 907.2K |
Complementary Tools for Palisade Stock analysis
When running Palisade Bio's price analysis, check to measure Palisade Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palisade Bio is operating at the current time. Most of Palisade Bio's value examination focuses on studying past and present price action to predict the probability of Palisade Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palisade Bio's price. Additionally, you may evaluate how the addition of Palisade Bio to your portfolios can decrease your overall portfolio volatility.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |